Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Combined Open-Label and Double-Blind, Placebo-Controlled Crossover Study Assessing the Effectiveness, Safety, and Tolerability of Oral Fasudil in Subjects With Dementia and Wandering Behaviors of Elopement and/or Getting Lost

NCT04793659 is registered in ClinicalTrials.gov with Woolsey Pharmaceuticals as lead sponsor.

NCT NCT04793659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04793659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Combined Open-Label and Double-Blind, Placebo-Controlled Crossover Study Assessing the Effectiveness, Safety, and Tolerability of Oral Fasudil in Subjects With Dementia and Wandering Behaviors of Elopement and/or Getting Lost
Lead sponsor
Woolsey Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2020
Completion date
February 11, 2022
Enrollment
24 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

dementia